Foghorn Therapeutics Inc. FHTX
Set alert
2.10 USD -0.03 -1.41%
As of Nov 3, 2:03 PM ET
2.09 Day range 2.20
1.79 52-week range 7.61
- YTD
- -61.11%
- 1 year
- -50.12%
- Open
- 2.15
- Prev close
- 2.13
- Mkt cap
- 124.71M
- Vol
- 337.26K
- Avg vol
- 735.91K
- EPS
- -0.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.09
- High
- 2.20
- Forward P/E
- -3.12
- Beta
- 3.15
- Short ratio
- 7.62
- Inst. own
- 72.09%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 7.50
- 200-d avg
- 6.85
- 1y target
- 12.00
Analyst view
Consensus: buy
Buy
Price target (mean) 12.00 +471.4% upside
Now 2.10
- Target (low)
- 4.00
- Target (mean)
- 12.00
- Target (high)
- 18.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.27333 | -0.33 – -0.23 | -0.57 | +52.0% | 8.14M | +41.0% | 3 |
| Next quarter | -0.24 | -0.24 – -0.24 | -0.59 | +59.3% | 5.45M | +7.9% | 1 |
| Current year | -1.56 | -1.79 – -1.35 | -2.34 | +33.3% | 29.65M | -13.2% | 5 |
| Next year | -1.11 | -1.82 – -0.75 | -1.56 | +28.7% | 32.94M | +11.1% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 16, 2024 | Jefferies | Maintained | Buy | Buy |
| Sep 24, 2024 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 3, 2024 | Jefferies | Initiated | — | Buy |
| Aug 19, 2024 | Evercore ISI Group | Initiated | — | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 9, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| May 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 10, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 8, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 13, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 6, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jun 29, 2023 | Goldman Sachs | Maintained | Buy | Buy |
| Jun 28, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 8, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 9, 2023 | Wedbush | Maintained | — | Outperform |
| May 9, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 25, 2023 | BMO Capital | Maintained | — | Outperform |
| Apr 25, 2023 | Wedbush | Maintained | — | Outperform |
| Mar 28, 2023 | B of A Securities | Initiated | — | Buy |
| Mar 10, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 10, 2023 | Wedbush | Maintained | — | Outperform |
| Jan 5, 2023 | BMO Capital | Initiated | — | Outperform |
| Nov 21, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Aug 24, 2022 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Aug 10, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 24, 2022 | Goldman Sachs | Maintained | — | Buy |